Zafgen (ZFGN) reports Q4 loss per share of 39c, to suspend plans to file IND application for ZGN-1258
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Zafgen Reports Fourth Quarter and Full Year 2018 Operating and Financial Results and Provides Key Program and Business Updates
March 11, 2019 4:05 PM EDTRecently announced positive results for second cohort of Phase 2 clinical trial of ZGN-1061
Updates on progress preparing for FDA Type A meeting for ZGN-1061
Suspends IND filing plans for ZGN-1258 based on nonclinical finding in long-term toxicology studies
Expanded executive team with highly experienced drug development leader, Dr. Priya Singhal, as Head of Research and Development
Company to host conference call today at 5:00 p.m. ET
BOSTON, March 11, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:... More
